Oral Valganciclovir Versus Valacyclovir

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2007
To determine if the rate of cytomegalovirus reactivation during treatment with alemtuzumab (Campath) is reduced by the use of valganciclovir prophylaxis.
Epistemonikos ID: c2d3072231d26dbb64d819f2d333ba73c433b0cb
First added on: Nov 24, 2021